Switzerland's Anergis Closes Series A Funding For Allergy Vaccine Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Anergis raises CHF 18 million from European venture funds to support Phase II study of fast-acting approach to allergy desensitization.